Impact Factor
4.42
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
9.90
1,181 total citations
h5-index
41
h5 depth signal
Cited share
89.5%
111 of 124
Total citations
1,181
Citation footprint
Metric signal
11.74
External metric anchor
Self-citation
2.4%
28 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
198
China
70
United Kingdom
67
Germany
58
Italy
55
Citing Fields of Research
Immunology
153
Oncology
134
Pharmacology & Toxicology
114
Medical Ethics
85
Immunotherapy
79
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,700
Articles tracked across the journal lifetime
Indexed publication set
124
111 cited publications
Last 12 months
67
5.6 publications/month
Open access share
61.2%
41 OA publications in the last year
Leading citing country
United States
198 citing publications
Leading citing field
Immunology
153 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v15n1, 2001-
v15n1, 2001-
Active Coverage
Research Focus & Classification
Indexed Subjects
Immunology
Immunotherapy
Inflammatory Bowel Diseases & Infections
Musculoskeletal Disorders
Oncology
Medical Ethics
Pharmacology & Toxicology
Broad Categories
Allergy and Immunology
Drug Therapy
Genetics, Medical
Therapeutics
Separation Techniques
Immunology
Musculoskeletal Disorders
Immunotherapy
Lysosomal Storage Disorders
MeSH Descriptors
Biological Products
Genetic Therapy
Immune System Diseases
Immunotherapy
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
DOI 10.1007/s40259-026-00803-y
Open DOI
From Reflection to Implementation: Tailored Clinical Development of a Pembrolizumab Biosimilar Candidate
03
DOI 10.1007/s40259-026-00811-y
Open DOI
Plant-Based Systems for Producing Therapeutic Proteins: Current Status and Future Prospects
04
DOI 10.1007/s40259-026-00806-9
Open DOI
Biosimilars: A Virtuous Cycle of Sustainability and Innovation
05
06
DOI 10.1007/s40259-026-00804-x
Open DOI
Biologic Therapies for Alleviating Neurodegeneration in Lysosomal Storage Diseases
07
DOI 10.1007/s40259-026-00802-z
Open DOI
The Effect of Anti-drug Antibodies on the Bioavailability of Alglucosidase Alfa in Classic Infantile Pompe Disease
Background The impact of anti‑drug antibodies (ADAs) on the bioavailability of recombinant human acid α-glucosidase (rhGAA) in classic infantile Pompe disease remains incompletely understood. Objective The aim of this study was to invest...
08
DOI 10.1007/s40259-026-00798-6
Open DOI
Targeting MYC-Driven Cancers: From Oncogenic Addiction to Therapeutic Vulnerability
09
10
Bibliographical & Catalog Notes
Title from cover.
Also issued online.